MCM
LRMR icon

MAI Capital Management’s Larimar Therapeutics LRMR Stock Holding History

MAI Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32K Buy
10,479
+9,967
+1,947% +$39.6K ﹤0.01% 2022
2026
Q1 		$2.3K Buy
512
+511
+51,100% +$2.04K ﹤0.01% 3867
2025
Q4 		$4 Buy
+1
New +$4 ﹤0.01% 4337

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

MAI Capital Management's LRMR Position: Q2 2026 in Review

MAI Capital Management increased its Larimar Therapeutics (LRMR) stake by 1,947% in Q2 2026, buying an estimated $39.6K and bringing the position to 10,479 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #2022.

MAI Capital Management first reported a position in LRMR in Q4 2025 and has held it in 3 quarters since. 162 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • MAI Capital Management held 10,479 shares of Larimar Therapeutics worth $32K as of Q2 2026.
  • MAI Capital Management bought 9,967 Larimar Therapeutics shares in Q2 2026, an estimated $39.6K.
  • Larimar Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #2022 holding.
  • MAI Capital Management first reported a position in Larimar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.